TabletsClinical Overview
Teneligliptin (20 mg) is a third-generation, highly selective, orally active dipeptidyl peptidase-4 (DPP-4) inhibitor. It features a unique J-shaped conformation that binds to subsite S1, S2, and S2-extensive pockets of the DPP-4 enzyme, achieving powerful enzyme inhibition (>80% at 24 hours) with a half-life of 24.2 hours. It is eliminated through dual hepatic and renal pathways, allowing standard once-daily dosing across all stages of chronic kidney disease (CKD) without dose adjustments. Indicated for type 2 diabetes mellitus as monotherapy or in combination with other oral antidiabetic agents.
Active Pharmaceutical Ingredients
Verified Clinical References
Usage Guidelines
Take orally once daily with or without food with water, at the same time each day. No dose titration or renal adjustment is necessary.
General Administration Advice: Adhere strictly to the prescribed dosage, frequency, and treatment course. For oral medications, swallow with sufficient water. Never stop antibiotics, psychiatric medications, or antihypertensives abruptly without clinical direction.
Possible Side Effects
Common: Hypoglycemia (when combined with sulfonylureas), headache, nasopharyngitis, constipation, abdominal distension. Rare/Severe: Acute pancreatitis, intestinal obstruction, and severe arthralgia.
*Note: Individual physiological responses vary. While many patients experience few or no side effects, notify your treating physician if adverse reactions persist or if hypersensitivity (angioedema, skin rash, dyspnea) occurs.
Precautions & Warnings
Caution in patients with cardiac conduction abnormalities; supratherapeutic doses (160 mg) can cause transient QT prolongation. Discontinue if severe, persistent abdominal pain occurs.
Schedule H (Prescription Required)
This medication is scheduled under statutory drug regulatory frameworks (CDSCO / Drugs & Cosmetics Rules). Dispensing requires a valid medical prescription from a registered medical practitioner. Self-medication or unsupervised dosage adjustment carries significant clinical risks.
Medical Disclaimer: Statutory Clinical Disclaimer: The information provided is for educational and price-transparency purposes only and does not constitute medical advice, clinical diagnosis, or treatment recommendations. Always consult a registered endocrinologist, diabetologist, or qualified physician before initiating, adjusting dosages of, or substituting any antidiabetic or hormonal medication.
Teneligliptin Tablets 20mg
Teneligliptin (20 mg) is a third-generation, highly selective, orally active dipeptidyl peptidase-4 (DPP-4) inhibitor. It features a unique J-shaped conformation that binds to subsite S1, S2, and S2-extensive pockets of the DPP-4 enzyme, achieving powerful enzyme inhibition (>80% at 24 hours) with a half-life of 24.2 hours. It is eliminated through dual hepatic and renal pathways, allowing standard once-daily dosing across all stages of chronic kidney disease (CKD) without dose adjustments. Indicated for type 2 diabetes mellitus as monotherapy or in combination with other oral antidiabetic agents.
Teneligliptin 20mg + Metformin Hydrochloride 500mg (Sustained Release) Tablets
Metformin Hydrochloride and Teneligliptin combines an insulin sensitizer with a long-acting peptidomimetic DPP-4 inhibitor. Teneligliptin possesses a unique "J-shaped" chemical structure with five consecutive binding anchors on the DPP-4 enzyme, providing potent and prolonged (>24 hour) incretin stabilization without requiring dose reduction in renal impairment, while metformin controls fasting hyperglycemia. Indicated for type 2 diabetes mellitus in adult patients.
Teneligliptin 20mg + Metformin Hydrochloride 1000mg (Sustained Release) Tablets
Metformin Hydrochloride and Teneligliptin combines an insulin sensitizer with a long-acting peptidomimetic DPP-4 inhibitor. Teneligliptin possesses a unique "J-shaped" chemical structure with five consecutive binding anchors on the DPP-4 enzyme, providing potent and prolonged (>24 hour) incretin stabilization without requiring dose reduction in renal impairment, while metformin controls fasting hyperglycemia. Indicated for type 2 diabetes mellitus in adult patients.
Dapagliflozin Tablets 10 mg
Dapagliflozin (5 mg, 10 mg) is a pioneer selective sodium-glucose co-transporter 2 (SGLT2) inhibitor on the WHO Model List of Essential Medicines. It acts in the S1 segment of the renal proximal tubule, blocking glucose and sodium reabsorption and promoting the urinary excretion of 70 to 80 grams of glucose per day. In addition to glycemic reduction, it induces osmotic diuresis, decreases intraglomerular pressure, reduces cardiac preload and afterload, and confers landmark cardio-renal protection. Indicated for type 2 diabetes mellitus, heart failure with reduced or preserved ejection fraction (HFrEF/HFpEF), and chronic kidney disease (CKD) to slow renal decline.